Your browser is no longer supported. Please, upgrade your browser.
Settings
RARE Ultragenyx Pharmaceutical Inc. daily Stock Chart
RARE [NASD]
Ultragenyx Pharmaceutical Inc.
Index- P/E- EPS (ttm)-6.20 Insider Own1.60% Shs Outstand40.95M Perf Week4.03%
Market Cap2.64B Forward P/E- EPS next Y-6.54 Insider Trans-9.21% Shs Float38.49M Perf Month-4.61%
Income-245.90M PEG- EPS next Q-1.71 Inst Own84.90% Short Float14.41% Perf Quarter-6.00%
Sales0.10M P/S26429.13 EPS this Y-56.90% Inst Trans0.29% Short Ratio9.27 Perf Half Y2.36%
Book/sh11.62 P/B5.55 EPS next Y7.50% ROA-47.70% Target Price85.93 Perf Year-7.24%
Cash/sh9.28 P/C6.95 EPS next 5Y53.40% ROE-52.80% 52W Range46.52 - 91.35 Perf YTD-8.21%
Dividend- P/FCF- EPS past 5Y- ROI-52.30% 52W High-29.34% Beta-
Dividend %- Quick Ratio6.70 Sales past 5Y- Gross Margin- 52W Low38.74% ATR3.08
Employees376 Current Ratio6.70 Sales Q/Q- Oper. Margin- RSI (14)46.40 Volatility3.20% 4.48%
OptionableYes Debt/Eq0.00 EPS Q/Q-23.00% Profit Margin- Rel Volume0.51 Prev Close65.68
ShortableYes LT Debt/Eq0.00 EarningsMay 18 AMC Payout- Avg Volume598.37K Price64.54
Recom2.20 SMA204.03% SMA50-12.04% SMA200-7.84% Volume302,400 Change-1.74%
Apr-19-17Downgrade Wedbush Outperform → Neutral $80 → $75
Apr-19-17Downgrade H.C. Wainwright Buy → Neutral $88 → $72
Apr-06-17Downgrade Jefferies Buy → Hold
Mar-23-17Downgrade Piper Jaffray Overweight → Neutral
Nov-14-16Downgrade Citigroup Neutral → Sell
Jul-07-16Initiated Piper Jaffray Overweight $70
Jun-28-16Initiated BofA/Merrill Buy
May-10-16Reiterated Wedbush Outperform $99 → $92
Mar-08-16Initiated Robert W. Baird Outperform $85
Feb-19-16Initiated Leerink Partners Outperform $80
Feb-09-16Initiated H.C. Wainwright Buy $104
Jan-21-16Initiated Credit Suisse Outperform
Jan-12-16Upgrade Citigroup Sell → Neutral
Dec-22-15Initiated Canaccord Genuity Buy $126
Dec-01-15Initiated Stifel Buy $125
Oct-23-15Resumed Jefferies Buy $108
Sep-03-15Initiated Citigroup Sell
Sep-01-15Initiated Raymond James Outperform $125
Jul-27-15Downgrade Morgan Stanley Overweight → Equal-Weight
Jul-13-15Reiterated Sun Trust Rbsn Humphrey Buy $82 → $119
Apr-27-17 08:30AM  Ultragenyx Initiates Global Phase 3 Study of UX007 in Glut1 DS Patients with Disabling Movement Disorders GlobeNewswire
Apr-26-17 10:30AM  What's in Store for Nivalis (NVLS) this Earnings Season? Zacks
Apr-20-17 11:02AM  Company News for April 20, 2017 Zacks
Apr-19-17 04:45PM  Energy, biotech, financials & more in the trader blitz CNBC Videos
12:14PM  Analyst Sees Ultragenyx Shares Range Bound Despite Positive Data Benzinga
10:38AM  Ultragenyx's Hypophosphatemia Drug Succeeds in Phase III Zacks
10:30AM  Why Ultragenyx Pharmaceutical Stock Is Spiking Today Motley Fool
09:52AM  The Next Steps For Ultragenyx' Burosumab Following Positive Phase 3 Data Benzinga
09:50AM  Biotech Movers: Ultragenyx Jumps on Phase Three Burosumab Data TheStreet.com
Apr-18-17 05:37PM  Ultragenyx surges on positive results for hypophosphatemia drug test MarketWatch
05:23PM  After-hours buzz: IBM, LRCX, RARE & more CNBC
04:01PM  Ultragenyx, Kyowa Hakko Kirin and Kyowa Kirin International Announce Positive 24-week Data from Adult Phase 3 Study of Burosumab (KRN23) in X-linked Hypophosphatemia PR Newswire
04:01PM  Ultragenyx, Kyowa Hakko Kirin and Kyowa Kirin International Announce Positive 24-Week Data from Adult Phase 3 Study of Burosumab (KRN23) in X-Linked Hypophosphatemia GlobeNewswire
Apr-10-17 09:34AM  Ultragenyx's (RARE) XLH Drug Positive in Phase II Study Zacks
08:30AM  Ultragenyx Appoints Deborah Dunsire, M.D., to Board of Directors GlobeNewswire
Apr-06-17 08:30AM  Ultragenyx and Kyowa Kirin International Announce Positive Data from Pediatric Phase 2 Studies of Burosumab (KRN23) in X-Linked Hypophosphatemia GlobeNewswire -5.06%
08:30AM  Ultragenyx and Kyowa Kirin International Announce Positive Data from Paediatric Phase 2 Studies of Burosumab (KRN23) in X-Linked Hypophosphatemia PR Newswire
Mar-24-17 08:15AM  Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : RARE-US : March 24, 2017 Capital Cube
Mar-23-17 03:34PM  Is It Time To Buy Ultragenxy? Barrons.com -8.13%
09:36AM  Ultragenyx's Seizure Candidate UX007 Fails in Phase II Study Zacks
09:36AM  Biotech Premarket Movers: Insys, Ultragenyx, Alexion TheStreet.com
08:43AM  Ultragenyxs Seizure Drug Fails Study Investopedia
Mar-22-17 05:15PM  Ultragenyx falls on results of seizure medication study MarketWatch
05:04PM  Ultragenyx seizure drug fails mid-stage study Reuters
04:24PM  Ultragenyx seizure drug fails mid-stage study
04:05PM  Ultragenyx Announces Topline Data from Phase 2 UX007 Glucose Transporter Type-1 Deficiency Syndrome Seizure Study GlobeNewswire
Mar-02-17 08:30AM  Ultragenyx to Present at Upcoming Investor Conferences GlobeNewswire
Feb-22-17 01:04PM  ULTRAGENYX PHARMACEUTICAL INC. Financials
Feb-21-17 11:56AM  Baron Opportunity Fund Comments on Ultragenyx Pharmaceutical
Feb-17-17 06:06AM  ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 10-K, Annual Report
12:01AM  Edited Transcript of RARE earnings conference call or presentation 16-Feb-17 10:00pm GMT
Feb-16-17 04:42PM  Ultragenyx reports 4Q loss
04:10PM  ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
04:05PM  Ultragenyx Reports Fourth Quarter and Full Year 2016 Financial Results and Corporate Update GlobeNewswire
07:07AM  Q4 2016 Ultragenyx Pharmaceutical Inc Earnings Release - After Market Close
Feb-15-17 08:47AM  Drug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More
Feb-10-17 08:30AM  Ultragenyx to Present at Leerink Partners Global Healthcare Conference GlobeNewswire
Feb-09-17 04:07PM  Ultragenyx to Host Conference Call for Fourth Quarter and Full Year 2016 Financial Results and Corporate Update GlobeNewswire
Feb-01-17 07:33AM  Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : RARE-US : February 1, 2017
Jan-06-17 08:18AM  Ultragenyx's (RARE) KRN23 Accepted for Review in the EU
Jan-05-17 08:18AM  Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : RARE-US : January 5, 2017
02:00AM  Ultragenyx and Kyowa Kirin International Announce Marketing Authorization Application for KRN23 Filed and Accepted for Review by European Medicines Agency GlobeNewswire
02:00AM  Ultragenyx and Kyowa Kirin International Announce Marketing Authorisation Application for KRN23 Filed and Accepted for Review by European Medicines Agency PR Newswire
Jan-04-17 08:30AM  Ultragenyx to Present at J.P. Morgan Healthcare Conference GlobeNewswire +7.83%
Dec-23-16 07:41AM  Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : RARE-US : December 23, 2016
Dec-14-16 11:58AM  ETFs with exposure to Ultragenyx Pharmaceutical, Inc. : December 14, 2016
Dec-13-16 10:50AM  Ultragenyx Pharmaceutical, Inc. Value Analysis (NASDAQ:RARE) : December 13, 2016
Dec-12-16 01:08PM  Should You Buy MB Financial, Inc. (MBFI)? at Insider Monkey
07:45AM  Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : RARE-US : December 12, 2016
Dec-09-16 08:51AM  Hedge Funds Are Dumping Ultragenyx Pharmaceutical Inc (RARE) at Insider Monkey
Dec-02-16 04:18PM  ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Dec-01-16 10:17AM  Ultragenyx (RARE) Reports Positive Phase II Study on UX007
Nov-30-16 08:30AM  Ultragenyx Announces Positive Data from Phase 2 Study of UX007 in Long-Chain Fatty Acid Oxidation Disorder Patients GlobeNewswire -7.01%
Nov-29-16 08:15AM  Blog Coverage Lion Biotechnologies Signs a New Manufacturing Services Agreement with WuXi AppTec for its Cell Therapy Products Accesswire
Nov-14-16 05:08PM  ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:15AM  Ultragenyx Pharma downgraded by Citigroup
Nov-11-16 08:30AM  Ultragenyx Announces Withdrawal of Marketing Authorization Application for Aceneuramic Acid Prolonged Release (Ace-ER) in the European Union GlobeNewswire
07:12AM  Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : RARE-US : November 11, 2016
Nov-08-16 08:30AM  Ultragenyx to Present at Upcoming Investor Conferences GlobeNewswire
06:10AM  ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 10-Q, Quarterly Report
02:36AM  Edited Transcript of RARE earnings conference call or presentation 7-Nov-16 10:00pm GMT
Nov-07-16 04:52PM  Ultragenyx reports 3Q loss +5.95%
04:21PM  ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
04:05PM  Ultragenyx Reports Third Quarter 2016 Financial Results and Corporate Update GlobeNewswire
07:07AM  Q3 2016 Ultragenyx Pharmaceutical Inc Earnings Release - After Market Close
Nov-04-16 08:54AM  Drug Stocks Earnings Roster for Nov 7: HZNP, ACAD & More
Oct-31-16 08:30AM  Ultragenyx to Host Conference Call for Third Quarter 2016 Financial Results and Corporate Update GlobeNewswire -5.80%
Oct-26-16 08:30AM  Ultragenyx Announces First Patient Enrolled in Global Phase 3 Study of KRN23 in Pediatric Patients with X-Linked Hypophosphatemia (XLH) GlobeNewswire
Oct-18-16 11:00AM  ETFs with exposure to Ultragenyx Pharmaceutical, Inc. : October 18, 2016
Oct-13-16 08:28AM  Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : RARE-US : October 13, 2016
Oct-12-16 04:22PM  Biotechs Worst-Performing Stocks Wednesday; Prothena, Supernus Fall -6.47%
Oct-05-16 03:35PM  Fidelity Denies Report It Favored Its Venture Group Over Mutual Funds
Sep-27-16 08:30AM  Ultragenyx to Present at Leerink Partners Roundtable Series GlobeNewswire
Sep-20-16 01:46PM  Jefferies Highlights Clinically Meaningful Data From Ultragenyx On KRN23
11:32AM  Why Sarepta Approval is Good News for BioMarin, Alexion at Barrons.com
Sep-19-16 10:45AM  Ultragenyx Reports Positive Interim Data from Pediatric and Adult Phase 2 Studies of KRN23 in X-Linked Hypophosphatemia GlobeNewswire
Sep-18-16 11:15AM  Ultragenyx Reports Positive Interim Data from Phase 2 Study of KRN23 for the Treatment of Tumor-Induced Osteomalacia GlobeNewswire
Sep-16-16 08:30AM  Ultragenyx to Host Conference Call to Discuss KRN23 Data Presented at ASBMR 2016 Annual Meeting GlobeNewswire
Sep-14-16 04:27PM  Bevy Of Biotech Stocks Healthy; Sarepta, Bluebird, Exelixis Soar
02:05PM  Bevy Of Biotech Stocks Healthy; Sarepta, Bluebird, Exelixis Soar
Sep-01-16 10:05AM  Discretionary Stocks Boost the Wells Fargo Growth Fund in YTD 2016
08:30AM  Ultragenyx to Present at Baird 2016 Global Healthcare Conference GlobeNewswire
Aug-23-16 08:30AM  Ultragenyx Announces KRN23 Data Presentations at ASBMR 2016 Annual Meeting GlobeNewswire
Aug-22-16 02:57PM  After Medivation, These 6 Biotech Stocks Could Be M&A Targets Next at Barrons.com
Aug-12-16 05:16PM  ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Aug-09-16 08:30AM  Ultragenyx to Present at Upcoming Investor Conferences GlobeNewswire
06:10AM  ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 10-Q, Quarterly Report
Aug-08-16 10:27PM  Edited Transcript of RARE earnings conference call or presentation 8-Aug-16 9:00pm GMT
04:57PM  Ultragenyx reports 2Q loss
04:13PM  ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
04:05PM  Ultragenyx Reports Second Quarter 2016 Financial Results and Corporate Update GlobeNewswire
07:07AM  Q2 2016 Ultragenyx Pharmaceutical Inc Earnings Release - After Market Close
Aug-06-16 09:15AM  9 Top Picks of Credit Suisse Still Have 50% Implied Upside or Much More! at 24/7 Wall St.
Aug-05-16 09:24AM  5 Drug Stocks Reporting Q2 Earnings on Aug 8: AGN & More
Aug-03-16 02:47PM  ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Other Events
Aug-01-16 12:20PM  Heres What Were Looking For From Ultragenyx Pharmaceutical Inc (RARE) at Insider Monkey
08:30AM  Ultragenyx to Host Conference Call for Second Quarter 2016 Financial Results and Corporate Update GlobeNewswire
Jul-28-16 08:30AM  Ultragenyx Announces Completion of Enrollment in Phase 3 Study of KRN23 in Adults with X-Linked Hypophosphatemia (XLH) GlobeNewswire
08:30AM  How Focusing On Obscure Diseases Made BioMarin A $15 Billion Company at Forbes
Jul-27-16 08:30AM  Ultragenyx Announces Completion of Enrollment in Phase 3 Study of Aceneuramic Acid Extended Release (Ace-ER) in GNE Myopathy GlobeNewswire +7.41%
Ultragenyx Pharmaceutical Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is developing various biologics product candidates, including KRN23, a human monoclonal antibody that in Phase III adult study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia. Its biologics product candidates also comprise recombinant human beta -glucuronidase (rhGUS), an enzyme replacement therapy, which completed the Phase 3 clinical study for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A (rhPPCA), an enzyme replacement therapy, which is in preclinical development for galactosialidosis. The company is also developing range of small-molecule product candidates, such as UX007, a substrate replacement therapy that is in Phase II study for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and aceneuramic acid extended-release (Ace-ER), an oral formulation of sialic acid, which is in Phase III extension study to treat GNE myopathy. It has collaboration and license agreements with Arcturus Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Kyowa Hakko Kirin Co. Ltd.; Saint Louis University; Baylor Research Institute; Nobelpharma Co., Ltd.; Alcami Corporation; HIBM Research Group; and St. Jude Children's Research Hospital. The company was founded in 2010 and is headquartered in Novato, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Huizenga Theodore AlanController and PAOMar 09Sale86.342,500215,8459,709Mar 10 05:04 PM
Sharp ShaliniCFO & Executive Vice PresidentMar 02Option Exercise0.8212,0009,78067,887Mar 03 04:36 PM
Sharp ShaliniCFO & Executive Vice PresidentMar 02Sale90.1012,0001,081,17655,887Mar 03 04:36 PM
Sharp ShaliniCFO & Executive Vice PresidentDec 23Option Exercise0.816,5005,26551,887Dec 23 04:14 PM
Aliski WilliamDirectorDec 05Option Exercise21.006,000126,00065,985Dec 05 05:39 PM
Aliski WilliamDirectorDec 05Sale78.196,000469,16059,985Dec 05 05:39 PM
Huizenga Theodore AlanController and PAONov 16Option Exercise21.002,00042,00013,134Nov 18 04:11 PM
Huizenga Theodore AlanController and PAONov 16Sale79.732,000159,46011,134Nov 18 04:11 PM
KAKKIS EMIL DPresident & CEONov 15Sale81.2920,0001,625,753447,147Nov 17 04:01 PM
Sharp ShaliniCFO & Executive Vice PresidentNov 09Option Exercise0.8224,00019,56069,387Nov 10 11:18 AM
Sharp ShaliniCFO & Executive Vice PresidentNov 09Sale71.2024,0001,708,89445,387Nov 10 11:18 AM
Sharp ShaliniCFO & Senior Vice PresidentOct 19Option Exercise0.8212,0009,78057,387Oct 21 04:00 PM
Sharp ShaliniCFO & Senior Vice PresidentOct 19Sale61.4012,000736,82045,387Oct 21 04:00 PM
KAKKIS EMIL DPresident & CEOOct 14Sale63.0220,0001,260,360467,147Oct 18 04:01 PM